Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2469-2481

  Hreiche, Raymond ^a,b   Plante, Isabelle ^a,b   Drolet, Benoit ^c,d   Morissette, Pierre ^a,b   Turgeon, Jacques ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Drug interaction; Drug targeting; In vitro in vivo correlations (IVIVC); Pharmacodynamics; Physiological model

Indexed keywords

ACECAINIDE; DELAYED RECTIFIER POTASSIUM CHANNEL; DOFETILIDE; DOMPERIDONE; ERYTHROMYCIN; KETOCONAZOLE;

ACTION POTENTIAL; ANIMAL TISSUE; ARTICLE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; GUINEA PIG; HEART REPOLARIZATION; HUMAN; HUMAN CELL; LONG QT SYNDROME; MALE; NONHUMAN; PATCH CLAMP;

EID: 79954553037     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22437     Document Type: Article

References (47)

1. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR. 2004. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475-495.
2. Roden DM. 2004. Drug-induced prolongation of the QT interval. N Engl J Med 350:1013-1022.
3. Selzer A, Wray HW. 1964. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17-26.
4. Hohnloser SH, Singh BN. 1995. Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6:920-936.
5. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 2002. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
6. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. 1990. Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790.
7. Bishop RO, Gaudry PL. 1989. Prolonged Q-T interval following astemizole overdose. Arch Emerg Med 6:63-65.
8. Drolet B, Zhang S, Deschenes D, Rail J, Nadeau S, Zhou Z, January CT, Turgeon J. 1999. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 10:1597-1604.
9. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. 1998. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97:204-210.
10. + channels in atrial cells of guinea pig heart. Jpn J Physiol 40:479-490.
11. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195-215.
12. Chinn K. 1993. Two delayed rectifiers in guinea pig ventricular myocytes distinguished by tail current kinetics. J Pharmacol Exp Ther 264:553-560.
13. Weerapura M, Hebert TE, Nattel S. 2002. Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Arch 443:520-531.
14. Gillis AM. 2000. Effects of antiarrhythmic drugs on QT interval dispersion-relationship to antiarrhythmic action and proarrhythmia. Prog Cardiovasc Dis 42:385-396.
15. Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. 2003. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 41:934-937.
16. Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. 2001. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther 6:255-260.
17. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. 2000. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102:1883-1885.
18. Geelen P, Drolet B, Rail J, Berube J, Daleau P, Rousseau G, Cardinal R, O'Hara GE, Turgeon J. 2000. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 102:275-277.
19. Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J. 1999. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288:1261-1268.
20. Khalifa M, Drolet B, Daleau P, Lefez C, Gilbert M, Plante S, O'Hara GE, Gleeton O, Hamelin BA, Turgeon J. 1999. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 288:858-865.
21. + current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 75:879-886.
22. Daleau P, Turgeon J. 1994. Triamterene inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Circ Res 74:1114-1120.
23. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. 1992. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238.
24. Woosley RL, Chen Y, Freiman JP, Gillis RA. 1993. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
25. Owens RC Jr. 2004. QT prolongation with antimicrobial agents: understanding the significance. Drugs 64:1091-1124.
26. Daleau P, Lessard E, Groleau MF, Turgeon J. 1995. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91:3010-3016.
27. Dumaine R, Roy ML, Brown AM. 1998. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 286:727-735.
28. Geelen P, Drolet B, Lessard E, Gilbert P, O'Hara GE, Turgeon J. 1999. Concomitant block of the rapid (I(Kr)) and slow [I(Ks)] components of the delayed rectifier potassium current is associated with additional drug effects on lengthening of cardiac repolarization. J Cardiovasc Pharmacol Ther 4:143-150.
29. Fournier P, Pacouret G, Charbonnier B. 1993. A new cause of torsades de pointes: Combination of terfenadine and troleandomycin. Ann Cardiol Angeiol (Paris) 42:249-252 (in French).
30. Feroze H, Suri R, Silverman DI. 1996. Torsades de pointes from terfenadine and sotalol given in combination. Pacing Clin Electrophysiol 19:1519-1521.
31. Yap YG, Camm AJ. 2003. Drug induced QT prolongation and torsades de pointes. Heart 89:1363-1372.
32. Abriel H, Schlapfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, Stoller R, Kappenberger L. 2004. Molecular and clinical determinants of drug-induced long QT syndrome: An iatrogenic channelopathy. Swiss Med Wkly 134:685-694.
33. Rubart M, Pressler ML, Pride HP, Zipes DP. 1993. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 88:1832-1844.
34. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. 2002. Safety of nonantiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview. Drug Saf 25:263-286.
35. De Ponti F, Poluzzi E, Montanaro N. 2000. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1-18.
36. Sanguinetti MC, Mitcheson JS. 2005. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26:119-124.
37. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. 2000. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97:12329-12333.
38. Margulis M, Sorota S. 2008. Additive effects of combined application of multiple hERG blockers. J Cardiovasc Pharmacol 51:549-552.
39. Ducroq J, Printemps R, Le Grand M. 2005. Additive effects of ziprasidone and D, l-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current. J Pharmacol Toxicol Methods 52:115-122.
40. Grube M, Meyer zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K, Rosskopf D, Eckel L, Bohm M, Jedlitschky G, Kroemer HK. 2006. Uptake of cardiovascular drugs into the human heart: Expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 113:1114-1122.
41. Koepsell H, Schmitt BM, Gorboulev V. 2003. Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36-90.
42. Jonker JW, Schinkel AH. 2004. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2-9.
43. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. 1981. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 6:61-70.
44. Schäfer-Korting M, Korting HC, Dorn M, Mutschler E. 1984. Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol 22:371-374.
45. Austin KL, Mather LE, Philpot CR, McDonald PJ. 1980. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 10:273-9.
46. Allen MJ, Nichols DJ, Oliver SD. 2000. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 50:247-253.
47. Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. 1980. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 46:463-468.